Mendelian randomization

Jump to: navigation, search

In epidemiology, Mendelian randomization is "the use of the genetic variation of known functions or phenotypes to correlate the causal effects of those functions or phenotypes with a disease outcome"[1][2]. Mendelian randomization controlls for extraneous influences when a true controlled experiment, or a sequence of randomized clinical trials, cannot be carried out. The method takes its name from Gregor Mendel, the father of modern genetics.

Background

An important focus of observational epidemiology is the identification of modifiable causes of common diseases that are of public health interest. In order to have firm evidence that a recommended public health intervention will have the desired beneficial effect, the observed association between the particular risk factor and disease must imply that the risk factor actually causes the disease.

Well-known successes include the identified causal links between smoking and lung cancer, and between blood pressure and stroke. However, there have also been notable failures when identified exposures were later shown by randomised controlled trials (RCTs) to be non-causal. For instance, it has now been shown that hormone replacement therapy will not prevent cardiovascular disease, as was previously thought, and may have other adverse health effects. The reason for such spurious findings in observational epidemiology is most likely to be confounding social, behavioural or physiological factors which are difficult to control for and particularly difficult to measure accurately. Moreover, many findings cannot be replicated by RCTs for ethical reasons.

Implementing Mendelian randomization

Mendelian randomization is a method that allows one to test for, or in certain cases to estimate, a causal effect from observational data in the presence of confounding factors. It uses common genetic polymorphisms with well-understood effects on exposure patterns (e.g., propensity to drink alcohol) or effects that mimic those produced by modifiable exposures (e.g., raised blood cholesterol). Importantly, the genotype must only affect the disease status indirectly via its effect on the exposure of interest. Because genotypes are assigned randomly when passed from parents to offspring during meiosis, the population genotype distribution should be unrelated to the confounders that typically plague observational epidemiology studies. In this regard, Mendelian randomization can be thought of as a “natural” RCT. The method relies on getting good estimates from genetic association studies. Misleading conclusions can also be drawn in the presence of linkage disequilibrium, genetic heterogeneity, pleiotropy, or population stratification.

References

  1. Anonymous (2020), Mendelian Randomization Analysis (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Emdin CA, Khera AV, Kathiresan S (2017). "Mendelian Randomization". JAMA. 318 (19): 1925–1926. doi:10.1001/jama.2017.17219. PMID 29164242.

1. M.B. Katan (1986) Apolipoprotein E isoforms, serum cholesterol and cancer. Lancet, i:507-508.

2. J.E. Rossouw et al. (2002) Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women’s Health Initiative randomized controlled trial, Jama 288: 321-333.

3. G. Davey Smith and S. Ebrahim (2003) Mendelian randomization: can genetic epidemiology contribute to understanding environmental determinants of disease? International Journal of Epidemiology 32: 1-22.

4. D.C. Thomas and D.V. Conti (2004) Commentary: The concept of Mendelian randomization. International Journal of Epidemiology 32: 21-25

5. G. Davey Smith, S. Ebrahim, S. Lewis, A.L.Hansell, L.J. Palmer and P.R. Burton (2005) Genetic epidemiology and public health: hope, hype, and future prospects. Lancet 366: 1484-1498.

6. G. Davey Smith and S. Ebrahim (2005) What can Mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ 330: 1076-1079.

External links


Linked-in.jpg